anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cervix carcinoma has been a serious, long-term issue in the Czech Republic. About 1,000 new cases are diagnosed every year and about 400 female patients die as a result of the disease. More than 20,000 women in the Czech Republic live with a history of cervix carcinoma therapy and the potential risk of its recurrence. Although the past years have been marked with effective organisational changes in cervix carcinoma screening thanks to which a decreasing trend of its incidence can be observed, there is a lack of substantial impact on the occurrence of advanced stages of the disease and mortality. Similar data have also been reported internationally: foreign authors analysed cases of patients with a malignant cervix tumour. They reported that 24 - 32% of females with a diagnosed malignant tumour had periodically undergone cytological screening. The reason is that the sensitivity of an individual cytological examination for detecting severe pre-cancer is limited, ranging between 40 - 75% and only increasing with repeated examinations. The negative predictive value of the cytological swab is additionally limited and reaches 0.78% in recent studies over a three-year screening interval.

The cause of nearly all cervix carcinomas is human papilomavirus (HPV). Hence the detection of the HPV genome is a more prospective screening tool with higher sensitivity than a cytological swab. The sensitivity of the validated HPV DNA test using PCR method reaches 94.5% for detecting severe pre-cancer (confidence interval 94.2 - 96.9%). As shown by comparative studies, the sensitivity of the HPV DNA test for the detection of severe pre-cancer is 35% higher on average when compared to the cytological test. The HPV DNA test in addition shows a significantly better negative three-year predictive value (0.34%) and the low value continues for at least another five years. The lower specificity of the HPV DNA test can be compensated by selective genotype specification with proof of the most frequent oncogenic genotypes HPV 16 and HPV 18. This promising procedure, validated by large multicentric randomised studies and introduced to clinical practice in several European countries, primarily uses the detection of HPV DNA.

The study repeatedly determined the presence of the HPV genome, including the prevalence of selected HPV genotypes (16, 18 and other hrHPV) and conventional cytology. The relative sensitivity of the two methods was specified. In the course of the prospective follow-up, the incidence of pre-cancers and invasive tumours in the study population were specified.
In this multi-center, randomized, open-label, prospective clinical trial, a total of 60 relapsed/refractory AML patients will be randomized into 2 groups. Patients in the IAC arm receive the therapy consisting of idarubicin 10 mg/㎡/d on days 1-3, cytarabine 100mg/㎡/d on days 1-7 and cyclophosphamide at a dose of 350mg/㎡/d on the second day and the fifth day. In the control arm, patients received other physician-directed regimen including fludarabine, cytarabine with/without granulocyte stimulating factor(FLA±G) regimen,cytarabine plus daunorubicin(DA）regimen , decitabine,aclacinomycin and cytarabine(decitabine plus AA) regimen or AA regimen plus granulocyte stimulating factor. All the regimen in the control arm can not contain cyclophosphamide. The primary end point is complete remission. The second end points include overall survival, relapse-free survival and time to treatment failure.
An elderly man was referred to vascular surgery on incidental discovery of a left retroperitoneal mass ultimately found to be of left renal vein (LRV) origin. He initially presented with recurring lower back pain. CT of the abdomen/pelvis showed a 6.0×5.5 cm lobulated retroperitoneal mass anterior to the infrarenal aorta. Resection of the mass necessitated a multidisciplinary team consisting of medical oncologists, radiation oncologists, urologists and vascular surgeons. In efforts to obtain an R0 margin, en-bloc resection of the LRV from its confluence with the inferior vena cava (IVC) was necessary. A primary repair of the IVC was performed with preservation of the left kidney. The patient's back pain has since resolved after the surgery. A literature search found IVC reconstructions to be safe and effective in the removal of vascular leiomyosarcomas.
<P>PROBLEM TO BE SOLVED: To provide a compound having an effect as a modulator of a subtype of a specific nicotine receptor on a nicotine acetylcholine receptor (nAChR).  <P>SOLUTION: A new compound of 3-(4-pyranyloxy), 5-(3-pyrrolidinyl-2-ethylene)-pyridine is disclosed. The compound is a ligand of various nAChRs. The compound and its pharmaceutically acceptable salts can be used for preparing a medicinal composition and/or a drug for preventing or curing a disease relating to a functional disorder of the nAChR, especially a disease of central nervous system and gastrointestinal system. The disease that can be cured includes, for example, a neurodegenerative disease including a central nervous system disease such as Alzheimer's disease, a cognitive disorder, a movement disease such as Parkinson's disease, chemical poisoning, a behavior disorder and an inflammatory disease in gastrointestinal system. The compound can also serve as a painkiller in treatment of acute pain, a chronic or repetitive ache.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Women receiving a single dose of 1 gram of TA--includes all women that will get 1 gram dose of the TA during surgery. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
The first phase of the study is not randomized. In this phase, the first group of participants (n=10) will all participate in a tele-yoga class using an iPad loaned to them by the study. They will attend this treatment session from the comfort of their home or a location of their choice. Yoga treatment will last 12 weeks. At the end of treatment, veterans will provide feedback by completing a satisfaction questionnaire to rate various aspects of the teleyoga (e.g. technical challenges, ability to perform yoga through the video-conferencing platform, problems that occurred, and recommendations to improve the class, etc). The teleyoga protocol will be modified on the basis of this feedback and will be tested on a second group of participants (n=10). The second phase of the study will involve randomization of a further group of participants (n=30) to either the teleyoga developed in phase one, or in-person yoga.
Therapeutic compsns. for preventing bronchospasm are new, comprising 3-acetamido-6-methyl-8-propyl-s-triazolo 4,3-a pyrazine and atropine or hyoscine or one of their salts and a diluent. The triazolo-pyrazine is potentiated by atropine or hyoscine. Oral administration is pref. the dose of triazolopyrazine being 0.2-10 mg/kg and that of atropine or hyoscine 0.0002 to 0.05 mg/kg usually admin. as sulphate hydrobromide, methonitrate or methobromide. A unit dose of the compsn. contains 15-150 mg of triazolo-pyrazine (A) (I) and 0.02-1 mg of hyoscine or atropine (II) esp. 50 mg of (A) and 0.6 mg of (B). The compsns. have been tested and synergy demonstrated against carbachol-induced bronchospasm in the guinea-pig.
A minimum of 3,000 children will be recruited to the BIVA-ED (Biomarker Validation in Emergency Department) study, in order to capture sufficient children with confirmed bacterial infection. Additional children with less common febrile illnesses will also be recruited: 500 critically ill (BIVA-PIC); 200 at high-risk of bacterial illness through primary or secondary immunodeficiency (BIVA-HR); 150 with an inflammatory diagnosis, whose initial presentation is difficult to discriminate from bacterial infection (BIVA-INF). Samples collected from recruits in the BIVA studies will be used for the validation of biomarkers (clinical, proteomic and transcriptomic biomarkers) for diagnosis of febrile illness, including markers of bacterial and viral infection (confirmed by culture and/or molecular microbiology) and inflammatory conditions.
PROBLEM TO BE SOLVED: To obtain the coating powder resistant to the moisture-absorbing solidification and the evaporation of components in processing and storage and keeping the effect of a core substance over a long period in eating by coating a core substance exhibiting solid state at normal temperature with a powdery lipid having a melting point of >=40 deg.C in the presence of a specific oil and fat. SOLUTION: A core substance which is solid at normal temperature (e.g. perfume, acidulant, vitamin, etc., taking crystalline or powdery state at normal temperature) is coated with a powdery lipid having a melting point of preferably >=40 deg.C (preferably a hardened animal or vegetable oil such as hardened rapeseed oil) in the presence of a molten resin having a melting point of >=40 deg.C (preferably 40-100 deg.C). Preferably the sum of the powdery lipid and the molten oil and fat is 0.1-5 pts.wt. based on 1 pt.wt. of the core substance and the amount of the molten oil and fat is 0.1-5 pts.wt. based on 1 pt.wt. of the powdery lipid. The particle size of the core substance is preferably 30-150 mesh and the particle diameter of the powdery lipid is preferably 10-100μm.  A flavor-improving effect having excellent quick and durable effect can be attained by adding a perfumery substance to the molten resin.
All control patients had undergone neurotrauma with or without basilar skull fracture, or had neurosurgery, at least three weeks earlier. All patients were vaccinated with two vaccines at the same time, 0,5 ml PPSV23 and 0,5 ml Act-HIB which is a conjugate vaccine against H. influenzae type b. They were vaccinated at least three weeks after trauma or surgery. The vaccines were administered by subcutaneous injections.
Selected patients will undergo a CPET evaluation. The initial CPET will identify patients with underlying ischemia and serve as a baseline study. Ischemia will be assessed using: 1) peak VO2: measures the peak transport of O2 to the tissues when O2 extraction from the blood is maximal; 2) the anaerobic threshold (AT): measures the sustainable work capacity in units of VO2; 3) the O2-pulse measurements at the AT peak VO2: estimate stroke volume at those levels of exercise; and 4) the relationship of O2 uptake to work rate (ΔVO2/ΔWR): provides information on the ability of the cardiac output to increase. Patients whoseCPET results meet the criteria for ischemia will be started on Ranexa 500mg BID and advanced within one week +/-4 days to 1000mg BID. A second CPET will be performed after 4 weeks +/- 4 days of maximum therapy. CPET results before and after therapy will undergo a statistical comparison. The initial off treatment CPET measurement will serve as the control to assess changes found during therapy. No medication changes or revascularization procedures will occur during the study. If patients require and undergo a medication change or a revascularization procedure, they will be excluded from the study.

Patients will be contacted at the completion of week one prior to up titration, then at the end of week two to ensure tolerance and compliance with the 1000mg BID dose. Patients will perform the second CPET study at week four +/- 1 week. The trial medication will be assessed and counted to ensure that patients have taken there allotted pill count for the duration of the study. Patients who are found to be noncompliant of less than 80% will be excluded from the study.
Background: shoulder sub acromial impingement syndrome is an encroachment of subacrormial tissues, rotator cuff, subacrormial bursa, and the long head of the biceps tendon, as a result of narrowing of the subacrormial space. Activities requiring repetitive or sustained use of the arms over head often predispose the rotator cuff tendon to injury. Objective of the study: To examine the influence of extra corporeal Shock wave versus phonophoresis on pain severity and functional disability in patients with sub acromial impingement syndrome. Subjects and Methods: Thirty patients diagnosed as shoulder impingement syndrome stage II Neer classification due to mechanical causes. Patients were randomly distributed into two equal groups. The first group consisted of 15 patients with a mean age of 45.46 (+ 8.64) received therapeutic exercises( stretching exercise of posterior shoulder capsule and strengthening exercises of shoulder muscles) and shockwave therapy (6000 shock, 2000/session, 3 sessions, 2 weeks a part, 0.22mJ/mm2) years. The second group consisted of 15 patients with a mean age of 46.26 (+ 8.05) received same therapeutic exercises and phonophoresis (3 times per week, each other day, for 4 consecutive weeks). Patients were evaluated pretreatment and post treatment for shoulder pain severity, shoulder functional disability, shoulder flexion, abduction and internal rotation motions.
OBJECTIVE: The study delved into the epigenetic factors associated with periodontal disease in two lineages of mice, namely C57bl/6 and Balb/c. Its primary objective was to elucidate alterations in the methylome of mice with distinct genetic backgrounds following systemic microbial challenge, employing high-throughput DNA methylation analysis as the investigative tool.
METHODS: Porphyromonas gingivalis (Pg)was orally administered to induce periodontitis in both Balb/c and C57bl/6 lineage. After euthanasia, genomic DNA from both maxilla and blood were subjected to bisulfite conversion, PCR amplification and genome-wide DNA methylation analysis using the Ovation RRBS Methyl-Seq System coupled with the Illumina Infinium Mouse Methylation BeadChip.
RESULTS: Of particular significance was the distinct methylation profile observed within the Pg-induced group of the Balb/c lineage, contrasting with both the control and Pg-induced groups of the C57bl/6 lineage. Utilizing rigorous filtering criteria, we successfully identified a substantial number of differentially methylated regions (DMRs) across various tissues and comparison groups, shedding light on the prevailing hypermethylation in non-induced cohorts and hypomethylation in induced groups. The comparison between blood and maxilla samples underscored the unique methylation patterns specific to the jaw tissue. Our comprehensive methylome analysis further unveiled statistically significant disparities, particularly within promoter regions, in several comparison groups.
CONCLUSION: The differential DNA methylation patterns observed between C57bl/6 and Balb/c mouse lines suggest that epigenetic factors contribute to the variations in disease susceptibility. The identified differentially methylated regions associated with immune regulation and inflammatory response provide potential targets for further investigation. These findings emphasize the importance of considering epigenetic mechanisms in the development and progression of periodontitis.
Cisplatin, 80 mg/m2/day, intravenous (IV), every 3 weeks; capecitabine, 1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle. Study drugs were administered for at least 24 weeks.
This study was a quasi-experimental study with two groups of pretest and posttest to facilitate sampling from the emergency room of Mackay Memorial Hospital. Emergency nurses at Taipei Mackay Memorial Hospital were in the experimental group, and emergency nurses at Tamsui Mackay Memorial Hospital were in the control group. These cases are expected to be accepted. There were 54 people in the experimental group and 54 people in the control group. The experimental group received a two-week mindfulness-based mobility device-assisted program. The program is a mobile application developed by researchers and designed for use on smartphones, tablets, and other mobile devices. The program content is facilitated and guided by certified instructors from the Center for Mindfulness (CFM) at the University of Massachusetts Medical School. Five suitable sound files were provided to guide subjects in practicing mindfulness. Each audio file is approximately 10 to 15 minutes in length. The control group did not take any intervention measures. The experimental group was tested on the scale before and after the program, and the control group was also measured at the same time. Research tools include the Nursing Stress Scale, Psychological Distress Scale, and Compassion Exhaustion Scale. The SPSS 20.0 software package was used for statistical analysis and processing of the data, and covariates were used to analyze the results. The findings will help improve mental health by reducing stress, psychological distress and compassion fatigue among emergency nurse practitioners caring for COVID-19 patients.
BACKGROUND: The glymphatic clearance pathway is a waste clearance system that allows for removal of soluble proteins such as amyloid β (Aβ) from the brain. Higher Aβ levels are associated with cognitive dysfunction in Parkinson's disease (PD). Diffusion tensor imaging-along the perivascular space (DTI-ALPS) is an imaging measure proposed to indirectly measure glymphatic function.
OBJECTIVES: Evaluate differences in DTI-ALPS-index between PD and healthy controls (HC) and characterize relationships between this proposed measure of glymphatic clearance, cognition, and disease severity in PD.
METHODS: PD (n = 32) and HC (n = 23) participants underwent brain imaging to assess DTI-ALPS. PD participants were classified as PD-normal cognition (PD-NC; n = 20) or PD-mild cognitive impairment (PD-MCI; n = 12) based on a Level II comprehensive cognitive assessment. A subgroup of PD participants (n = 21) returned for annual assessments for up to 4 years after baseline. Longitudinal outcomes included changes in performance on the comprehensive cognitive assessment and changes in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS).
RESULTS: PD participants had lower DTI-ALPS-index compared to HC. PD participants classified as PD-MCI had significantly lower DTI-ALPS-index compared to PD-NC. Lower DTI-ALPS-index at baseline was associated with longitudinal cognitive decline and worse longitudinal disease severity.
CONCLUSIONS: Glymphatic clearance, as measured with DTI-ALPS, has potential to serve as a marker of longitudinal disease progression. Interventions targeting glymphatic function should be explored for potential to slow cognitive decline in PD. © 2024 International Parkinson and Movement Disorder Society.
The purpose of this study is to examine the feasibility of and to establish methods for a future study that will investigate associations between oral bacteria and allergic diseases in children. Rates of allergic diseases such as asthma, hay fever, and eczema have increased in the U.S. over the past several decades. One explanation for those increases is the Hygiene Hypothesis, which contends that decreases in microbial exposures have made the population more reactive to environmental allergens. Reports of protective associations for various infections and exposures to farms, pets, siblings, and day care have provided support for the Hypothesis. Preliminary work by NIEHS researchers suggests that some oral bacterial exposures may be beneficial. NIEHS researchers recently reported that elevated serum antibody concentrations to two common oral pathogens were associated with lower prevalences of asthma, wheeze, and hay fever in the U.S. population. Using a mouse model, NIEHS researchers found that immune responses involved in allergic airway inflammation could be modulated by infection with an oral pathogen. To further investigate these associations in humans, NIEHS researchers, in collaboration with UNC researchers, are planning an observational study that will collect saliva samples from and allergy information on child patients at the UNC-Chapel Hill School of Dentistry. Because we anticipate that several hundred children might have to be enrolled, we are proposing to test methods in a pilot study of 60 children. Twenty children will be recruited from each of three pediatric clinics. A research assistant will obtain the parent's consent and the child's assent and administer a questionnaire to the parent. The child's dentist will collect one teaspoon of saliva by having the child chew a piece of inert wax and spit into a sterile collection cup. Samples will be transported to the NIEHS and analyzed for bacterial species and for allergy-related cytokines. The specific aims for this pilot study are: 1) to identify the most efficient recruitment strategies, 2) to estimate response rates, 3) to estimate the distribution of allergic diseases among the children, 4) to identify any problematic consent form and questionnaire items, 5) to optimize saliva collection and laboratory protocols, and 6) to estimate statistical parameters required for more precise sample size calculations. Information gained from this pilot study will allow us to decide whether a larger study among this clinic population is feasible and to design a more efficient study if we decide to proceed.
1,253,990. Acetylenic carbamates. SMITH KLINE & FRENCH LABORATORIES Ltd. 9 Dec., 1969 [10 Dec., 1968], No. 58730/68. Heading C2C. Novel acetylenic carbamates of the general Formula (I): where R is phenyl, lower alkyl phenyl, halophenyl, 2-phenyl cyclopropyl, 2-(lower alkyl phenyl) cyclopropyl or 2 - (halophenyl)- cyclopropyl, R 1 , R 2  and R 3  are the same or different lower alkyl groups, R 4  and R 5  are either both methyl or ethyl or R 4  is methyl and R 5  is hydrogen and X- is a pharmaceutically acceptable anion may be prepared by reacting an isocyanate RCNO or acid azide RCON 3  with an alcohol of the general Formula (II): wherein Y is +NR 1 R 2 R 3  Lower alkyl is a C 1  to C 4  alkyl group. The compounds of the general Formula (III): wherein Z is halogen or a tertiary amino NR 1 R 2 , may be used to prepare compounds I when Z is a halogen by direct reaction with a tertiary amine NR 1 R 2 R 3  or by reaction with a secondary amine R 1 R 2 NH to give III when Z is tertiary amino-NR 1 R 2  followed by a lower alkyl ester of an inorganic acid R 3 X. Compound III may be prepared by reacting an amine RNH 2  with a haloformate of the general formula wherein Z is halogen. Compound III in which Z is tertiary amino may also be prepared as for I using II in which Y is NR 1 R 2  3 - Ethyl - 6 - dimethylaminohex - 4 - yn - 3 - ol is prepared by reacting 3-ethyl-pentyn-3-ol with formaldehyde and dimethylamine. Pharmaceutical compositions of compounds I with a diluent are hypertensive agents and may be administered parenterally.